{
    "clinical_study": {
        "@rank": "164999", 
        "arm_group": [
            {
                "arm_group_label": "Induction Group"
            }, 
            {
                "arm_group_label": "Consolidation Group"
            }, 
            {
                "arm_group_label": "Salvage Group"
            }, 
            {
                "arm_group_label": "Maintenance Group"
            }, 
            {
                "arm_group_label": "Alleviatitive Group"
            }
        ], 
        "brief_summary": {
            "textblock": "It is a prospective, non-interventional, open-label study, in order to observe the safety\n      and response in FLT3-ITD mutation positive AML patients who receiving sorafenib as\n      induction, consolidation, salvage, maintenance or alleviative treatment. The duration of the\n      study from June 2014 through May 2019, with the  recruitment duration from June 2014 to May\n      2017. The inclusion criteria is:\n\n        1. Definitely diagnosed as AML\n\n        2. FLT3-ITD mutation has been confirmed\n\n        3. Accepting the prescription of sorafenib"
        }, 
        "brief_title": "Sorafenib to Treat FLT3-ITD AML", 
        "completion_date": {
            "#text": "August 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myeloid Leukemia", 
            "FLT3-ITD Mutation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Definitely diagnosed as AML\n\n          -  FLT3-ITD mutation has been confirmed\n\n          -  Accepting the prescription of sorafenib\n\n        Exclusion Criteria:\n\n          -  Can not take drugs orally\n\n          -  Can not follow the doctors' advices\n\n          -  Other reasons that investigators considered as contra-indications for this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients who diagnosed as AML with FLT3-ITD mutation and accepting the prescription of\n        sorafenib."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156297", 
            "org_study_id": "SZ3201"
        }, 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Suzhou", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "215006"
                }, 
                "name": "The First Affiliated Hospital of Soochow University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "5", 
        "official_title": "Sorafenib to Treat AML Patients With FLT3-ITD Mutation: a Non-interventional Cohort Study", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Overall Response Rate", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Progress-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156297"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Leukemia-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Median time to the onset of sorafenib resistance", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }
        ], 
        "source": "The First Affiliated Hospital of Soochow University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The First Affiliated Hospital of Soochow University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}